REG - Dr. Martens PLC - AGM Trading Update

Dr MartensAnnouncement

10/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250710:nRSJ4225Qa&default-theme=true

RNS Number : 4225Q  Dr. Martens PLC  10 July 2025

10 July 2025

Dr. Martens plc - AGM Trading Update

Trading in line with expectations; FY26 guidance unchanged

 

Dr. Martens plc will hold its AGM at 09.30am today at 1-11 Hawley Crescent,
Camden, London, NW1 8NP, and also provides the following update.

Trading since the start of this financial year has been in line with
expectations and all guidance for FY26 remains unchanged. On a regional basis,
we have continued to see positive trading in our Americas Direct to Consumer
("DTC") channel, driven by full price sales, particularly in Retail. Our EMEA
DTC business remains more variable, with our UK business in particular
continuing to experience a challenging trading backdrop. Our APAC business
continues to show good growth, with a particularly strong performance in South
Korea driven by our well-established shoes category here.

Looking forward, the Autumn/Winter order books globally are healthy. The EMEA
order book is up year-on-year, whilst the Americas order book is broadly in
line year-on-year and importantly is based on a much wider product range than
previously. As ever, our performance will be H2-weighted, particularly from a
profit perspective.

We are focused on embedding our new consumer-first Levers for Growth strategy,
which we outlined at our results on 5 June and which builds on the work
undertaken in FY25 to stabilise the business. The strategy capitalises on the
clear strengths of the business today and taps into the significant new
markets and profit pools that are available to us. It is centred on engaging
more consumers, driving more product purchase occasions, curating market-right
distribution and simplifying the operating model. Further details on our early
progress in these areas will be shared at our first half results in November.

 

 

Enquiries

 

Investors and analysts
 

Bethany Barnes, Director of Investor
Relations
                                +44 7825
187465
 
 
  bethany.barnes@drmartens.com

Beth Fionda, Investor Relations Manager
 
beth.fionda@drmartens.com

 

Press
 

Sodali &
Co

Ludo
Baynham-Herd

Oliver Banks
 
                                 drmartens@client.sodali.com

 
 
 
   +44 207 250 1446

 

 

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global
presence. "Docs" or "DMs" were originally produced for their durability for
workers, before being adopted by diverse youth subcultures and associated
musical movements. Today, Dr. Martens has transcended its roots while still
celebrating its proud history. It operates in over 60 countries and employs
over 3,650 people worldwide. Its operations are split across both
Direct-to-Consumer and wholesale channels, and in addition to its
world-renowned "1460" boot its product segments span shoes including the 1461
shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as
well as a growing line of bags and accessories. Further information can be
found at https://www.drmartensplc.com/ (https://www.drmartensplc.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTSSAFIUEISEDW